Journal of the American Heart Association · 2026
Periprocedural 24-Hour Change in Renalase Adds Incremental Value for Early Risk Stratification of Cardiovascular Magnetic Resonance-Defined Microvascular Obstruction in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Ye, Li Ruixuan, Fu Ru, Zhao Lin, Sheng Zhe, Fu Jie, Xu Kai, Liu Jia, Huang Wei, Chen Chenyang, Wen Juan, Zeng Lixiong, Ou Ziwei, Sun Na, Jiang Zhou, Zhu Can, Liu Ying, Wang Yuhong, Zhou HuiZhen, Wang Xiaohui, Jiang Weihong, Li Xiaogang
Аннотация
BACKGROUND: Renalase, a stress-responsive enzyme with cardioprotective effects, exhibits a postreperfusion surge that temporally parallels the maturation of microvascular obstruction (MVO). We investigated whether the periprocedural change in renalase (Δ-renalase) is independently associated with MVO after primary percutaneous coronary intervention (PPCI).
METHODS: This prospective cohort study enrolled 266 consecutive patients with ST-segment-elevation myocardial infarction within 12 hours of symptom onset undergoing PPCI at the Third Xiangya Hospital (August 2024 to July 2025). Serum renalase was measured before and 24 hours after PPCI. Cardiovascular magnetic resonance performed 2 to 5 days after PPCI was used to define MVO. All enrolled patients were followed for 90 days after hospital discharge.
RESULTS: The cohort had a mean age of 60.1 years, and 31.6% were women. MVO was identified in 118 patients (44.4%). In univariable analysis, Δ-renalase showed a significant overall association with MVO (P=0.002) without evidence of nonlinearity (P=0.743). After adjustment for a prespecified 9-covariate set, Δ-renalase was modeled using restricted cubic splines and showed an independent, nonlinear association with MVO (overall P=0.002; nonlinear P=0.001). MVO odds increased more steeply at Δ-renalase values >0 μg/mL. Adding Δ-renalase improved discrimination (Δ area under the receiver operating characteristic curve=0.045), overall accuracy (Brier score 0.214-0.197), and net benefit across 30% to 50% risk thresholds. Higher Δ-renalase was independently associated with greater infarct extent (% left ventricular mass) and, among patients with cardiovascular magnetic resonance-defined MVO, greater MVO extent (% left ventricular mass), as well as lower 90-day peak oxygen pulse. Sensitivity analyses were consistent, with no significant effect modifications.
CONCLUSIONS: In patients with ST-segment-elevation myocardial infarction treated with PPCI, periprocedural Δ-renalase is independently associated with cardiovascular magnetic resonance-defined MVO and improves risk stratification, supporting its potential for early risk prediction.
REGISTRATION: URL: https://www.clinical.trials.gov; Unique Identifier: NCT06669520.
METHODS: This prospective cohort study enrolled 266 consecutive patients with ST-segment-elevation myocardial infarction within 12 hours of symptom onset undergoing PPCI at the Third Xiangya Hospital (August 2024 to July 2025). Serum renalase was measured before and 24 hours after PPCI. Cardiovascular magnetic resonance performed 2 to 5 days after PPCI was used to define MVO. All enrolled patients were followed for 90 days after hospital discharge.
RESULTS: The cohort had a mean age of 60.1 years, and 31.6% were women. MVO was identified in 118 patients (44.4%). In univariable analysis, Δ-renalase showed a significant overall association with MVO (P=0.002) without evidence of nonlinearity (P=0.743). After adjustment for a prespecified 9-covariate set, Δ-renalase was modeled using restricted cubic splines and showed an independent, nonlinear association with MVO (overall P=0.002; nonlinear P=0.001). MVO odds increased more steeply at Δ-renalase values >0 μg/mL. Adding Δ-renalase improved discrimination (Δ area under the receiver operating characteristic curve=0.045), overall accuracy (Brier score 0.214-0.197), and net benefit across 30% to 50% risk thresholds. Higher Δ-renalase was independently associated with greater infarct extent (% left ventricular mass) and, among patients with cardiovascular magnetic resonance-defined MVO, greater MVO extent (% left ventricular mass), as well as lower 90-day peak oxygen pulse. Sensitivity analyses were consistent, with no significant effect modifications.
CONCLUSIONS: In patients with ST-segment-elevation myocardial infarction treated with PPCI, periprocedural Δ-renalase is independently associated with cardiovascular magnetic resonance-defined MVO and improves risk stratification, supporting its potential for early risk prediction.
REGISTRATION: URL: https://www.clinical.trials.gov; Unique Identifier: NCT06669520.